How does Adstiladrin (nadofaragene firadenovec) treat bladder cancer?
Adstiladrin is a gene therapy designed to deliver a working cancer-fighting gene directly into bladder cells. It uses a viral vector to deliver the DNA for interferon alfa-2b (IFNα2b) to cells in the bladder lining. Once the gene is taken up by these cells, they produce IFNα2b locally, which helps slow or stop tumor growth. The therapy is given as an intravesical treatment, meaning it is instilled into the bladder through a catheter so it can act at the tumor site.
What happens after the drug is put into the bladder?
After the treatment is placed in the bladder, bladder cells take up the delivered genetic material and begin producing IFNα2b in the local tissue. That interferon signaling supports anti-tumor activity, including effects on immune responses and cancer cell survival. The goal is to reduce tumor burden and delay progression, rather than relying only on systemic drug exposure.
What type of bladder cancer is it used for?
Adstiladrin is used for non–muscle-invasive bladder cancer that is high-risk and includes patients who do not respond to or are intolerant of BCG (bacillus Calmette-Guérin), or whose disease has become BCG-unresponsive. It is also described as a treatment option for patients with carcinoma in situ (CIS) with or without papillary tumors in this setting.
How is Adstiladrin different from BCG or chemotherapy?
Unlike BCG or systemic chemotherapy, Adstiladrin delivers a gene that makes interferon inside the bladder tissue itself. That local production approach is meant to create an anti-tumor environment directly where the tumor is, delivered through bladder instillation rather than an intravenous infusion.
How often is Adstiladrin given?
Adstiladrin is typically administered as a bladder instillation on a scheduled cycle (the regimen is described in prescribing materials and clinical trial protocols). The key point is that it is a periodic intravesical treatment rather than a daily or continuous therapy.
What side effects do patients most commonly ask about?
Because Adstiladrin is delivered into the bladder, side effects often relate to bladder irritation and urinary symptoms (such as urgency, frequency, discomfort, or pain with urination). Patients may also experience treatment-related fatigue or flu-like symptoms, which can occur with interferon-based immune effects.
Drug coverage, patents, and exclusivity
For up-to-date market and patent context around Adstiladrin, including intellectual property and pricing-related reporting, DrugPatentWatch.com is a useful reference: https://www.drugpatentwatch.com/